Tristel Plc · LSE:TSTL
Tristel — Investor Presentation (June 2025)
15 slides from Tristel's investor presentation, June 2025
Slide 1: Tristel Plc - Mello Investor Presentation
TRISTEL PLC - MELLO INVESTOR PRESENTATION Matt Sassone, CEO Julija Shabanova, Executive Director JUNE 2025 tristelgroup.com 1
Slide 2: Our Company
Our Company We are an infection prevention company. The entire purpose of our business is to prevent the transmission of microbes from one object or person to another. We achieve our mission by applying a very powerful biocidal chemistry – chlorine dioxide to the target environmental surface or medi
Slide 3: Our Products
Our Products Decontamination of medical Hospital surface disinfection: devices by hand sporicidal efficacy & sustainability Ambition: “Global market leader Ambition: “Global market leader in point of care decontamination in emerging niche - sporicidal of medical devices” surface disinfectants” trist
Slide 4: Landscape & Market Opportunity
Landscape & Market Opportunity c. £1bn c. £5bn IV poles Market Obs & gynae Market Mattresses Opportunity* Trans-vaginal ENT Opportunity * Radiology Nasendoscopes 23% Trans-rectal Hospital wide Skin-surface High touch A&E & Theatres points Trolleys Intubation u/sound probes 40% laryngoscopes 5% Ophth
Slide 5: How We Win
How We Win Medical Device Medical Surface How we win: Disinfection How we win: Disinfection Convenience Compatibility Efficacy Faster Disinfection at point Approved to be used Broader spectrum & Speed of action vs of procedure with ‘000s of devices sporicidal abilities typical methods Speed Complian
Slide 6: 10 Year Sales Growth Record
10 Year Sales Growth Record 45,000 40,000 35,000 30,000 10-year CAGR growth: Revenue £'000 25,000 20,000 11% 15,000 10,000 5,000 - 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 H1 H2 tristelgroup.com 6
Slide 7: Latest Financial Results – Interims
Latest Financial Results – Interims (6 months up to Dec 2024) Revenue up 8% to £22.6m (2023: £20.9m) Adjusted* profit before tax up 19% Reported profit before tax up 9% to £4.9m (2023: £4.1m) to £3.7m (2023: £3.4m) Adjusted* EBITDA up 14% to £6.3m Reported EBITDA £5.0m (2023: £5.5m), a margin of 28%
Slide 8: Creating Greater Value Creation
Creating Greater Value Creation Geographical Expansion Product Application • Gaining share in USA which • Value expansion with cleaning, remains our largest opportunity. digital traceability & new products. • Continue to invest in direct operations • Deepen adoption beyond (Spain, Austria, and India
Slide 9: USA Timeline
USA Timeline 2016 Initial 2023 Tristel ULT 2024 Submitted 2025 Tristel OPH approach JUN DeNovo SEP 510k for JUN launch to FDA for grant Tristel OPH at APIC Tristel ULT 2022 Tristel ULT 2023 First 2025 Tristel OPH 2025 First JUN DeNovo OCT manufacture MAY Clearance AUG manufacture submission & shippi
Slide 10: USA - Ultrasound Opportunity
USA- Ultrasound Opportunity Market Size Market Split Market Strategy (Ultrasound Scans requiring HLD) Approximately 270,000 ultrasound devices in North America. 2. Soaking (25%) Across 5,700 1. Trophon relevant hospitals (50%) 3. Wiping Manufacturing & with departments and/or Distribution partner us
Slide 11: USA – Customer Success Examples
USA– Customer Success Examples “I can confidently “Tristel ULT is faster “Purchasing Tristel ULT "Tristel has been a recommend Tristel ULT. and easier to use than has been a lifesaver! game changer for our both Cidex and Trophon, sonographers, providing The product is just as We run a super busy wit
Slide 12: USA - Ophthalmology Opportunity
USA- Ophthalmology Opportunity Market Size Market Split Market Strategy (Current methodologies) Ophthalmic devices that Mixed Sales Model touch the eye must undergo High-Level Disinfection (HLD) after every use. 1. Soaking 2. Low level Wipes Combining direct sales efforts with Specialized Circa 16m
Slide 13: Why invest?
Why invest? 1 Strong Market Position 2 3 4 Scalable Proven Track Record of Resilient, in a Niche with High Global Growth, Profitability and Defensive Barriers to Entry Strategy Shareholder Returns Business Model Technology is unique, patented, Regulatory approvals Consistent revenue Company operates
Slide 14: Forthcoming investor dates
Forthcoming investor dates Capital Markets Day will be hosted in the City of London on Tuesday 29 July 2025 Open Day for Tristel shareholders will be hosted at the Company's headquarters in Snailwell, Cambridgeshire on Wednesday 30 July 2025 Company will also provide an update on trading for the yea
Slide 15: Questions
Questions tristelgroup.com 16